Mosunetuzumab (NCT07566364)

Name: Mosunetuzumab trial for Lymphocytic Leukemia (NCT07566364)
Uploaded: 2026-10-31T16:03:08.999Z
Duration: 1 min 23 s
Description: Mosunetuzumab trial for Lymphocytic Leukemia (NCT07566364). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT07566364.

Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRD: a one-minute explainerNCT075663641 min

Mosunetuzumab trial for Lymphocytic Leukemia (NCT07566364). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma after at least two treatment lines, including continuous BTK-inhibitor treatment for at least 12 months. Residual disease must remain detectable in marrow.

The idea: mosunetuzumab links CD20-bearing cancer cells to T cells. It is added to BTK inhibition, with initial step-up injections and then dosing every three weeks. Researchers assess residual-disease clearance and safety. High disease burden is excluded.

This phase 2 study plans 30 patients. Mahesh Swaminathan leads at MD Anderson in Houston, the sole recruiting US site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.